Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Vectura provides update on GSK Litigation | ||
By: Nasdaq / GlobeNewswire - 13 Sep 2019 | Back to overview list |
|
Vectura provides update on GSK Litigation Chippenham, UK – 13 September 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces that following the award of US$89.7m in damages to Vectura by a jury in the US District Court for the District of Delaware on 3 May 2019, presiding US District Judge Richard Andrews has ruled on the parties’ post-trial motions:
Paul Fry, Vectura’s Chief Financial Officer and Interim Chief Executive Officer of Vectura, said: “The judge’s post-motions ruling further validates Vectura’s original decision to pursue this action with GSK. We will always take action to protect and defend our intellectual property and we will provide further updates on this matter in due course.” About the ruling: The US$89.7m jury award to Vectura was based on a 3% royalty rate applied to US sales of GSK’s infringing products from August 1, 2016 to December 31, 2018. Judge Andrews granted Vectura’s motion for supplemental damages based on GSK’s infringing sales from January 1, 2019 to May 16, 2019 at a 3% royalty rate, which results in approximately US$10.5m in additional damages payable to Vectura. Judge Andrews granted Vectura’s motion for an ongoing royalty rate of 3% on U.S. sales of GSK’s infringing products from May 17, 2019 to expiration of Vectura’s patent in mid-2021. Judge Andrews granted Vectura’s motion for pre-judgment interest at the prime rate, compounded quarterly, which results in approximately US$6.7m due to Vectura. Judge Andrews granted Vectura’s motion for post-judgment interest at the Treasury bill rate, compounded annually. This interest will accrue on the damages awarded by the jury, supplemental damages and prejudgment interest, and will accrue going forward until Vectura is compensated by GSK. Judge Andrews denied the following motions: GSK’s motion for judgment of non-infringement, GSK’s motion for judgment of obviousness, GSK’s motion for a finding of no wilful infringement, GSK’s motion for a new trial, GSK’s motion for a reduction in the amount of damages awarded by the jury, Vectura’s motion for enhanced damages, and Vectura’s motion for attorney’s fees. The parties have the right to appeal these decisions. - Ends- For more information, please contact: Consilium Strategic Communications +44 (0)20 3709 5700 Notes About GSK Litigation About Vectura Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |